Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Interim Management Statement

7 Nov 2008 07:00

RNS Number : 6725H
Stanelco PLC
07 November 2008
 



7th November 2008

STANELCO PLC ("the Company" or "the Group")

Interim Management Statement

The Board of Stanelco Plc today issues its interim management statement for the nine month period ended 30 September 2008.

Overview

The first nine months of the year saw 120% growth in sales revenue to £12.2m compared with the same period last year (2007: £5.6m). We continued to make progress in reducing our operating losses.

Divisional Performance

BioPlastics

Commercialisation of the bioplastics technology continues as the Company broadens its base of regular customers, which is now developed across a variety of European markets.

Sales of bioplastics, made directly by Stanelcoare now up 450compared to the same 9 month period last year. Direct sales in the third quarter were up 24% on the second quarter, reaching £1.4m year-to-date.

In the third quarter the Company opened a small sales office in the USA to begin the process of exploiting the emerging opportunity for sustainable bioplastics in North America. This renewed activity is being driven by an experienced plastics industry professional and is already creating an encouraging pipeline of trials.

We have continued to strengthen the BioPlastics division in the UK by recruiting further senior technical and customer support expertise with substantive relevant expertise.  

Further minor investment in development and testing equipment was also made at the UK development facility in the period. Development trials continue to establish pace and laboratory success, with a number of new products having moved to pre-commercial trials with several customers.

RF Applications

In RF Applications divisionthe strong enquiry book is gradually being converted into orders and we expect to see some benefit of that in the second half as the General Manager and newly appointed Sales Manager begin to achieve traction.

The optical fiber furnace market continues to show encouraging signs, driven by continued fiber demand in Asia. In the third quarter, Stanelco continued to strengthen its position in China with its first order for its new generation of higher capacity furnaces powered by Stanelco's new RF generator.

There is also growing interest in the newly developed mobile welding products. However, the long lead times from enquiry to order mean that this is likely to have limited impact on this financial year's results.

Financial Position

We continue to maintain a strong balance sheet. Our cash position at 30 September was £6.9mstrengthened since the half year by working capital movements related to stock reduction.

Outlook 

Our strategy is clear and good progress is being made. We continue to look for compatible and sensible investment opportunities.

We remain alert to the rapidly changing economic conditions throughout the worldbut we have not seen an impact on our business as yet. The Board's expectations for the financial performance for 2008 remain in line with those set earlier in the year.

Ends -

Paul Mines, Chief Executive, Stanelco plc

Clive Warner, Finance Director, Stanelco plc

Tel: +44 (0) 2380 867 100

Jonathon Brill/Caroline Stewart

Financial Dynamics

Tel: +44 (0) 20 7831 3113

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBFBPTMMIMBBP
Date   Source Headline
29th Jan 20157:00 amRNSOperational Update
22nd Jan 20157:00 amRNSPre-close Trading Statement
21st Jan 20154:35 pmRNSHolding(s) in Company
11th Dec 201410:11 amRNSChange of Adviser
14th Nov 20149:58 amRNSHolding(s) in Company
4th Nov 20147:00 amRNSTrading Update
3rd Sep 20147:00 amRNSInterim Results
12th Aug 20149:36 amRNSHolding(s) in Company
31st Jul 20147:00 amRNSContract progress for RF Technologies Business
24th Jul 20143:28 pmRNSTrading Update
6th Jun 20143:56 pmRNSHolding(s) in Company
7th May 20147:00 amRNSEMI Share Option Plan
23rd Apr 201412:26 pmRNSResult of AGM and Appointment of Director
23rd Apr 20147:00 amRNSTrading Update
31st Mar 20147:00 amRNSUpdated Corporate Presentation
28th Mar 20147:02 amRNSPosting of Notice of AGM & Annual Report
27th Mar 20147:00 amRNSPreliminary Results
24th Mar 201411:43 amRNSContract for Stanelco RF Technologies Division
19th Feb 20149:01 amRNSHolding(s) in Company
24th Jan 20147:00 amRNSPre-close Trading Statement
4th Dec 20133:37 pmRNSIssue of Shares to Director
28th Nov 20131:30 pmRNSDirector/PDMR Shareholding
27th Nov 20137:00 amRNSHolding(s) in Company
4th Nov 20137:00 amRNSTrading Update
31st Oct 201312:27 pmRNSTotal Voting Rights
2nd Oct 201312:47 pmRNSIssue of Shares to a Director
27th Sep 20138:51 amRNSTR-1: Notification of Major Interest in Shares
25th Sep 201312:33 pmRNSResult of General Meeting
2nd Sep 20137:10 amRNSNotice of General Meeting
2nd Sep 20137:00 amRNSInterim Results
26th Jul 20137:00 amRNSPurchase of Shares following Consolidation
18th Jul 20137:00 amRNSInterim Management Statement
20th Jun 20132:34 pmRNSIssue of Equity
20th Jun 201312:45 pmRNSResult of General Meeting
17th Jun 201312:01 pmRNSHolding(s) in Company
17th Jun 201311:59 amRNSHolding(s) in Company
23rd May 20137:01 amRNSCapital Reorganisation
23rd May 20137:00 amRNSSettlement with Landlord in Respect of Leases
26th Apr 20137:00 amRNSIssue of shares to a Director Total Voting rights
25th Apr 20134:10 pmRNSResult of AGM
25th Apr 20137:00 amRNSTrading Update
4th Apr 20137:00 amRNSResearch Grant Award
3rd Apr 20134:35 pmRNSNotice of AGM and Annual Report and Accounts
28th Mar 20137:10 amRNSDirector's Remuneration and Consultancy agreement
28th Mar 20137:01 amRNSPreliminary Results
23rd Jan 20137:00 amRNSPre-close Trading Statement
2nd Nov 20127:00 amRNSTrading Update
1st Oct 20123:24 pmRNSCompletion of Sale
27th Sep 20122:03 pmRNSResult of General Meeting
7th Sep 20127:00 amRNSProposed Sale of stake in Biotec Holding GmbH

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.